TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15465432

Group type: EXPERIMENTAL
Intervention: Low beta training (12-15 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha/theta training (8-11 Hz/5-8 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta1 training (15-18 Hz)
Number of subjects: 0
Study: 10796750

Group type: COMPARATOR
Intervention: Intrathecal Baclofen
Number of subjects: 132

Group type: COMPARATOR
Intervention: Tizanidine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Other drugs (Gabapentine, Clonidine, Diazepam, Amytal, oral Baclofen)
Number of subjects: 132
Study: 9288368

Group type: EXPERIMENTAL
Intervention: Toki‐shakuyaku‐san (TSS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8309899

Group type: EXPERIMENTAL
Intervention: Transcervical chorionic villus sampling (CVS)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Amniocentesis (AC)
Number of subjects: 800
Study: 2873015

Group type: EXPERIMENTAL
Intervention: Drug-treated group (hydrochlorothiazide, propranolol, methyldopa)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Drug-treated group
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 785
Study: 29626416

Group type: EXPERIMENTAL
Intervention: Continuous administration of 16 mU/min (Group I)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: 1 mU/min (Group II)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: 4 mU/min (Group III)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: 5 mU/min quarter‐hourly (Group IV)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Syringe pump (Group V)
Number of subjects: 900
Study: 25862769

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (general rehabilitation exercise)
Number of subjects: 31
Study: 25226604

Group type: EXPERIMENTAL
Intervention: Exercise-training group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 44
Study: 22401642

Group type: EXPERIMENTAL
Intervention: Rotigotine 3 mg/24 hours via transdermal patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotigotine 8 mg/24 hours via transdermal patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single large patch vs. 2 smaller patches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patch application sites (hip, shoulder, abdomen, flank, thigh, upper arm)
Number of subjects: 0
Study: 20412640

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 695
Study: 17333332

Group type: EXPERIMENTAL
Intervention: Tailored decision aid (DA)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control pamphlet
Number of subjects: 145
Study: 15592189

Group type: EXPERIMENTAL
Intervention: Tc-99m N-NOET
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tc-99m N-NOET with reinjection protocol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tc-99m N-NOET stress imaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tl-201
Number of subjects: 50
Study: 11930708

Group type: EXPERIMENTAL
Intervention: Maxillary expansion and protraction therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment)
Number of subjects: 40
Study: 9218016

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (Elmiron)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 8389104

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control day (no allergen)
Number of subjects: 0
Study: 2874085

Group type: EXPERIMENTAL
Intervention: Cefazolin (3 doses of 0.5 g)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Mezlocillin (3 doses of 1 g)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 31055949

Group type: EXPERIMENTAL
Intervention: Facebook advertising
Number of subjects: 302

Group type: COMPARATOR
Intervention: Mailing recruitment letters
Number of subjects: 302
Study: 27859893

Group type: EXPERIMENTAL
Intervention: Skin camouflage program (4 sessions)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 66
Study: 28690353

Group type: EXPERIMENTAL
Intervention: Unconditional cash transfer (Child Grant)
Number of subjects: 0
Study: 25509057

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham ES (placebo)
Number of subjects: 20
Study: 22166848

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (systolic blood pressure < 120 mm Hg)
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic blood pressure < 140 mm Hg)
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (HbA1c < 0.060)
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard glycemic control (HbA1c 0.070‐0.079)
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 4733

Group type: EXPERIMENTAL
Intervention: Combined intensive treatment of glycemia and blood pressure
Number of subjects: 4733
Study: 19384953

Group type: EXPERIMENTAL
Intervention: TYR Arg402Gln variant
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: SLC45A2 Phe374Leu variant
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: TYRP1 rs1408799
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: SLC45A2 1721 C>G
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: TYR Ser192Tyr
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: TYR haplotype carrying only the Arg402Gln variant allele
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: OCA2 Arg419Gln
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: ASIP g.8818 A>G
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Haplotype near ASIP (rs4911414[T] and rs1015362[G])
Number of subjects: 1673
Study: 17465473

Group type: EXPERIMENTAL
Intervention: Hyoscine butyl bromide injection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 200
Study: 15318679

Group type: EXPERIMENTAL
Intervention: E-mail survey delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post survey delivery (with e-mail access)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post survey delivery (without e-mail access)
Number of subjects: 0
Study: 11094012

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg rocuronium (adults)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.12 mg/kg rocuronium (children)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.12, 0.18, or 0.24 mg/kg rocuronium (children)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.06, 0.12, or 0.18 mg/kg rocuronium (adults)
Number of subjects: 72
Study: 9067498

Group type: EXPERIMENTAL
Intervention: BMSC
Number of subjects: 82
Study: 8354583

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg daily for 7 days
Number of subjects: 51
Study: 3720527

Group type: EXPERIMENTAL
Intervention: Morphine and d-amphetamine combination
Number of subjects: 10

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: d-amphetamine alone
Number of subjects: 10
Study: 30024233

Group type: EXPERIMENTAL
Intervention: Infographic letter
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control letter
Number of subjects: 3
Study: 28065453

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 26239594

Group type: EXPERIMENTAL
Intervention: Partly supervised exercise programme (6 weeks supervised, followed by 6 weeks self-administered)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Self-administered exercise programme (12 weeks)
Number of subjects: 51
Study: 23325435

Group type: EXPERIMENTAL
Intervention: Extended antibacterial prophylaxis for 48 hours or until thoracostomy tubes were removed (n = 125)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo (n = 126)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Extended antibacterial prophylaxis
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 21601826

Group type: EXPERIMENTAL
Intervention: Prophylactic cefazolin
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 18513146

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 2
Study: 16542127

Group type: EXPERIMENTAL
Intervention: Computer-assisted, tailored self-management intervention
Number of subjects: 335

Group type: COMPARATOR
Intervention: Health risk appraisal with feedback control
Number of subjects: 335
Study: 12657224

Group type: EXPERIMENTAL
Intervention: Clomipramine infusion (5mg in 5min) during head-up tilt test (Clom-HUT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional head-up tilt test (Con-HUT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Clomipramine infusion during tilt test
Number of subjects: 126
Study: 10722899

Group type: EXPERIMENTAL
Intervention: Consumption of a single low pH orange drink for 15 days, 2 times per day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Consumption of a single low pH orange drink for 15 days, 4 times per day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increasing frequency of consumption (2 vs 4 drinks per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Consumption of a single low pH orange drink for 15 days
Number of subjects: 16
Study: 9193243

Group type: EXPERIMENTAL
Intervention: Low-dose indomethacin sodium for the prevention of intraventricular hemorrhage
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Cranial ultrasonographic (US) scan
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia and abnormal cranial US scan
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Chorioamnionitis, treatment with surfactant, bronchopulmonary dysplasia, abnormal cranial US findings
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Cranial US findings (grade 3 to 4 intraventricular hemorrhage, periventricular leukomalacia, ventriculomegaly)
Number of subjects: 381
Study: 1586272

Group type: EXPERIMENTAL
Intervention: Standard-range lithium levels (0.8 to 1.0 mmol/L)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low-range lithium levels (0.4 to 0.6 mmol/L)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Standard-range lithium therapy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Onset of hypomanic symptoms
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Hypomanic symptoms
Number of subjects: 94

Group type: COMPARATOR
Intervention: Subclinically depressed symptoms
Number of subjects: 94
Study: 31779715

Group type: EXPERIMENTAL
Intervention: 30‐min cycling (EX)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30‐min cycling with dietary energy replacement (EX + R)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rest control (CON)
Number of subjects: 14
Study: 31098961

Group type: EXPERIMENTAL
Intervention: IV lidocaine infusion (5 mg·kg−1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Active placebo infusion (diphenhydramine 50 mg)
Number of subjects: 34
Study: 28931031

Group type: EXPERIMENTAL
Intervention: Scientific reframing intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Traditional informed consent procedure (control)
Number of subjects: 154
Study: 27107066

Group type: EXPERIMENTAL
Intervention: Continuous infusion RSB analgesia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All RSB groups (single-dose, repeated-dose, continuous infusion)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All patients (benign and cancer)
Number of subjects: 46
Study: 25060946

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/amlodipine 20/5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olmesartan 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 0
Study: 22272732

Group type: EXPERIMENTAL
Intervention: Adherence counseling (six 30 minute individual sessions with unlimited booster sessions)
Number of subjects: 60
Study: 19149823

Group type: EXPERIMENTAL
Intervention: Rimonabant plus nicotine patch (n = 369)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Rimonabant plus placebo patch (n = 366)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Rimonabant plus nicotine patch
Number of subjects: 755

Group type: COMPARATOR
Intervention: Rimonabant only
Number of subjects: 755
Study: 18565222

Group type: EXPERIMENTAL
Intervention: Tailored print communication
Number of subjects: 2881

Group type: EXPERIMENTAL
Intervention: Telephone motivational interviewing
Number of subjects: 2881

Group type: EXPERIMENTAL
Intervention: Combined tailored print communication and telephone motivational interviewing
Number of subjects: 2881

Group type: COMPARATOR
Intervention: Control group (received a tailored letter after the last posttest)
Number of subjects: 2881
Study: 16042027

Group type: EXPERIMENTAL
Intervention: Mild Alzheimer's disease (AD) patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cognitively intact age-matched controls
Number of subjects: 27

Group type: COMPARATOR
Intervention: Young controls
Number of subjects: 27
Study: 15382410

Group type: EXPERIMENTAL
Intervention: Static magnetic therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 10071698

Group type: EXPERIMENTAL
Intervention: 5-mL injectate
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10-mL injectate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of 5-mL and 10-mL injectates
Number of subjects: 50
Study: 7729938

Group type: EXPERIMENTAL
Intervention: Anthracycline-including regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CMF regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 0
Study: 1904477

Group type: EXPERIMENTAL
Intervention: melphalan alone
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: melphalan plus hexamethylmelamine
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: cyclophosphamide plus doxorubicin (CA)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: cisplatin with CA
Number of subjects: 726

Group type: COMPARATOR
Intervention: CA without cisplatin
Number of subjects: 726
Study: 7027894

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 23
Study: 31674052

Group type: EXPERIMENTAL
Intervention: SIBO+ IBS-D
Number of subjects: 77

Group type: COMPARATOR
Intervention: SIBO- IBS-D
Number of subjects: 77
Study: 31112105

Group type: EXPERIMENTAL
Intervention: Active Surveillance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Number of subjects: 0
Study: 28580646

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg subcutaneously
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fumaric acid esters (FAEs)
Number of subjects: 200
Study: 26376074

Group type: EXPERIMENTAL
Intervention: Stress dose hydrocortisone (tapering 7-day course)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Stress dose hydrocortisone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24085766

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 234

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 234
Study: 21888669

Group type: EXPERIMENTAL
Intervention: Stapler hepatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clamp‐crushing technique
Number of subjects: 0
Study: 19623694

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d) and Ritonavir (100 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg twice daily) with Atazanavir (300 mg/d) and Efavirenz (400 mg/d)
Number of subjects: 0
Study: 17277393

Group type: EXPERIMENTAL
Intervention: Targeted cancer therapies (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 0
Study: 15077933

Group type: EXPERIMENTAL
Intervention: Acupuncture alone (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acupuncture with continued symptomatic medication (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Symptomatic medication followed by acupuncture (Group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acupuncture (Groups A and B)
Number of subjects: 30
Study: 11910689

Group type: EXPERIMENTAL
Intervention: Esmolol intravenous (i.v.) at the dose of 150 micrograms.kg‐1
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal saline at 0.9% (control group)
Number of subjects: 29
Study: 9151051

Group type: EXPERIMENTAL
Intervention: PC-coated drains
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-coated drains
Number of subjects: 51
Study: 7960367

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: High consumption of eggs or fresh vegetables
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Pre-trial body mass index (BMI)
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: History of cancer in parents or siblings
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Low BMI
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 29584

Group type: EXPERIMENTAL
Intervention: Intake of pickled vegetables or mouldy foods
Number of subjects: 29584
Study: 2979286

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg b.d. for 4 weeks
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 30527153

Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 26252788

Group type: EXPERIMENTAL
Intervention: fedratinib 300 mg once daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: fedratinib 400 mg once daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: fedratinib 500 mg once daily
Number of subjects: 31
Study: 23337693

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (dose not specified)
Number of subjects: 597
Study: 21174055

Group type: EXPERIMENTAL
Intervention: Orofacial therapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no orofacial therapy)
Number of subjects: 99
Study: 18438561

Group type: EXPERIMENTAL
Intervention: Er:YAG laser + phosphoric acid etching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phosphoric acid etching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Er:YAG laser alone
Number of subjects: 0
Study: 16567772

Group type: EXPERIMENTAL
Intervention: Early PET followed by histologic/cytologic verification of lesions
Number of subjects: 465

Group type: COMPARATOR
Intervention: Traditional work-up (TWU) according to international guidelines
Number of subjects: 465
Study: 12588381

Group type: EXPERIMENTAL
Intervention: Cartoon version of the CDLQI
Number of subjects: 101

Group type: COMPARATOR
Intervention: Written version of the CDLQI
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Postal CDLQI (cartoon version)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Postal CDLQI (written version)
Number of subjects: 101
Study: 10553838

Group type: EXPERIMENTAL
Intervention: Group 1 STIM: 24 patients received a single injection of 20 mL of a mixture of 2% lidocaine and 0.5% bupivacaine with 1:200,000 epinephrine.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 2 STIM: 26 patients received 10 mL of the same solution injected after stimulation of each sciatic nerve component.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 2 STIM (two stimulations)
Number of subjects: 50
Study: 8706233

Group type: EXPERIMENTAL
Intervention: Individual counselling by lactation counsellors
Number of subjects: 250

Group type: COMPARATOR
Intervention: Routine group health education
Number of subjects: 250
Study: 1677903

Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine administered orally
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine administered sublingually
Number of subjects: 7

Group type: COMPARATOR
Intervention: 10 mg cetirizine administered orally or sublingually
Number of subjects: 7
Study: 6337608

Group type: EXPERIMENTAL
Intervention: 150 mg imipramine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 60 mg mianserin
Number of subjects: 45

Group type: COMPARATOR
Intervention: 150 mg nomifensine
Number of subjects: 45

Group type: COMPARATOR
Intervention: desipramine
Number of subjects: 45
Study: 30487023

Group type: EXPERIMENTAL
Intervention: Sufficient Sleep (SS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sleep Restriction (SR)
Number of subjects: 8
Study: 26541814

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0 mg/day
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Cariprazine 0.75 mg/day
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571